Immunotherapy duo aims to block melanoma return in High-Risk patients
NCT ID NCT02656706
First seen Jan 18, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This study tested whether a combination of two immunotherapy drugs, nivolumab and low-dose ipilimumab, can help prevent melanoma from returning after surgical removal. The trial enrolled 22 adults with high-risk stage III or resected stage IV melanoma. Participants received the drugs for six months, and researchers monitored side effects and how long patients remained cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rhode Island Hospital and The Miriam Hospital
Providence, Rhode Island, 02903/02906, United States
Conditions
Explore the condition pages connected to this study.